Teva stock: Barclays raises target for Teva stock from USD 42.00 to USD 47.00
Published on 10/22/2026 at 16:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Barclays raised its Teva target from USD 42.00 to USD 47.00 on October 15, 2026.
- Weltruza revenue reached USD 77.00 million in the second quarter of 2026, up 43.00 percent year over year.
- Teva stock was USD 39.77 on October 22, 2026, down 2.07 percent versus USD 40.62.
- Teva will publish third-quarter 2026 results on November 3, 2026.
Barclays raised its price target for Teva Pharmaceutical Industries from USD 42.00 to USD 47.00 on October 15, 2026, keeping an Overweight rating ahead of the company's third-quarter results, according to Markets Insider. The target lies 18.18 percent above the USD 39.77 stock price. Teva stock was trading at USD 39.77 on October 22, 2026 at 10:38 a.m. EDT, down 2.07 percent versus the USD 40.62 prior close on the NYSE.
Weltruza adds a growth figure
Teva's branded portfolio supplied a clear operating comparison in the second quarter of 2026. Weltruza generated USD 77.00 million in revenue, up 43.00 percent from the same quarter of 2025, according to CTech. The same report said Teva's innovative medicines portfolio exceeded USD 1.00 billion in quarterly revenue for the first time, also up 43.00 percent year over year.
Price sits below the yearly high
The October 22, 2026 quote places Teva at a USD 18.85 to USD 42.02 52-week range. At USD 39.77, the stock stands 5.35 percent below the high and has a market capitalization of USD 46.3 billion. Trading volume reached 1,537,865 shares by 10:38 a.m. EDT.
November 3 carries the next date
Teva will release its third-quarter 2026 results on November 3, 2026 at 7:00 a.m. ET and hold its conference call at 8:00 a.m. ET, according to the company's Teva announcement dated September 23, 2026. The timing gives investors a defined checkpoint for the revenue trajectory and the commercial ramp of newer medicines.
Teva and two large drugmakers
Teva's USD 46.3 billion market value is below Bristol-Myers Squibb's USD 127.6 billion and above Viatris's USD 21.3 billion as of October 22, 2026. The comparison places Teva between a diversified large-cap pharmaceutical group and a lower-value generics-focused peer, while the target increase keeps attention on the company's branded portfolio.
Target and revenue shape the setup
Barclays' USD 47.00 target and Weltruza's USD 77.00 million second-quarter revenue provide two measurable markers for the stock. The next company date is November 3, 2026, when Teva's third-quarter results will add a fresh operating period to the picture.
Market context: Market report S&P 500.
More news and analyses on Teva Pharmaceutical Industries stock
